NeoGenomics (NASDAQ:NEO) Rating Reiterated by Stephens

Stephens restated their overweight rating on shares of NeoGenomics (NASDAQ:NEOFree Report) in a research report sent to investors on Tuesday, Benzinga reports. Stephens currently has a $19.00 target price on the medical research company’s stock.

Several other research analysts also recently weighed in on NEO. Needham & Company LLC reissued a buy rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Tuesday. Craig Hallum initiated coverage on shares of NeoGenomics in a research report on Wednesday, May 1st. They set a buy rating and a $26.00 price objective on the stock. TD Cowen reduced their target price on NeoGenomics from $21.00 to $20.00 and set a buy rating for the company in a report on Wednesday, May 1st. BTIG Research lowered their price target on NeoGenomics from $23.00 to $21.00 and set a buy rating on the stock in a report on Thursday, May 2nd. Finally, Benchmark reissued a buy rating and set a $18.00 price target on shares of NeoGenomics in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $19.89.

Get Our Latest Stock Analysis on NeoGenomics

NeoGenomics Stock Performance

NASDAQ NEO opened at $17.50 on Tuesday. The company has a quick ratio of 7.22, a current ratio of 2.01 and a debt-to-equity ratio of 0.37. The business’s fifty day moving average is $14.11 and its two-hundred day moving average is $14.73. NeoGenomics has a 1 year low of $11.03 and a 1 year high of $21.22.

NeoGenomics (NASDAQ:NEOGet Free Report) last announced its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company had revenue of $164.50 million for the quarter, compared to analyst estimates of $161.82 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. NeoGenomics’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, analysts forecast that NeoGenomics will post -0.19 EPS for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. grew its position in NeoGenomics by 107.2% in the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after acquiring an additional 1,206 shares in the last quarter. Burkett Financial Services LLC bought a new stake in NeoGenomics in the fourth quarter worth $46,000. Quadrant Capital Group LLC boosted its holdings in NeoGenomics by 22.0% in the fourth quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after purchasing an additional 883 shares in the last quarter. PNC Financial Services Group Inc. increased its position in NeoGenomics by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock worth $136,000 after buying an additional 1,791 shares during the last quarter. Finally, Banque Cantonale Vaudoise raised its holdings in NeoGenomics by 10.2% during the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock valued at $244,000 after buying an additional 1,633 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

About NeoGenomics

(Get Free Report)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Further Reading

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.